Trxade Group, Inc. (NASDAQ: MEDS), a health services IT
company focused on digitalizing the retail pharmacy experience by
optimizing drug procurement, the prescription journey and patient
engagement in the U.S., today announced its financial results for
the fourth quarter (Q4) and year ended (FY) December 31, 2020.
Selected Financial Highlights
$ in Millions |
Q4 |
% Increase (Decrease) |
FY |
% Increase (Decrease) |
2020 |
|
2019 |
|
2020 |
|
2019 |
|
Revenues |
$2.0 |
|
$1.7 |
|
17.1 |
% |
$17.1 |
|
$7.4 |
|
130.3 |
% |
Gross Profit |
$0.1 |
|
$1.3 |
|
(90.0 |
%) |
$5.7 |
|
$4.9 |
|
17.2 |
% |
Gross Margin Percentage |
6.5 |
% |
76.5 |
% |
(91.5 |
%) |
33.3 |
% |
65.5 |
% |
(49.1 |
%) |
Net Loss |
($2.3 |
) |
($0.5 |
) |
(362.0 |
%) |
($2.5 |
) |
($0.3 |
) |
(791.6 |
%) |
Adjusted EBITDA* |
($1.4 |
) |
$0.2 |
|
(929.4 |
%) |
$0.1 |
|
$0.9 |
|
(89.7 |
%) |
*Adjusted EBITDA is a non-GAAP financial measure
and is described in relation to its most directly comparable GAAP
measure under “Use of Non-GAAP Financial Information” below.
Fourth Quarter 2020 and Subsequent Operational
Highlights
- Trxade continued to expand the Trxade drug procurement
marketplace nationwide, adding 328 new registered members in Q4
2020, bringing the total registered members to approximately
11,800+.
- Appointed technology entrepreneur and industry thought leader
James Ram, to lead the company's newly launched MedCheks
subsidiary, in its efforts to bring a Digital Health Passport to
market, allowing the holder to display vaccination and COVID-19
testing status.
- Trxade’s telehealth subsidiary Bonum Health signed a strategic
partnership to provide affordable telemedicine services to the
patients of approximately 100 Kinney Drug retail pharmacies in New
York and Vermont, and, the more than two million Rx discount card
members of Kinney's sister company, ProAct, Inc., a fully
integrated pharmacy benefits manager.
- Launched Trxade Prime, a revolutionary service offered by the
Company’s wholesale division, allowing the registered members on
the Trxade platform to process, consolidate and ship orders that
are placed directly with Trxade Suppliers.
- Announced partnership with SingleCare, a free prescription
savings service, to supplement Bonum Health’s enterprise telehealth
solutions with prescription discounts offered to national, regional
and local pharmacies to promote the benefit to uninsured patients
and underserved communities.
Management Commentary
“2020 was a milestone year for our company as we
continued to innovate, grow and expand. Despite the
challenges of a global pandemic, we increased revenues by 130% for
the year, a testament to our team’s continued innovation and
development of our breakthrough digital healthcare services IT
platform. As we continue to scale exciting new affiliated services,
such as our telehealth platform or our recently announced digital
health passport initiative, we anticipate continued top line growth
in the coming year.
“I am particularly pleased to announce the
launch of our new subsidiary, MedCheks, which is developing a
digital health passport to help facilitate the safe reopening of
the global economy. To head this new initiative, we brought on
James Ram. Under his lead, the Digital Health Passport is planned
to leverage both state-of-the-art encryption and blockchain
technology to conceal all private health data, allowing for the
secure exchange of data between passport holder and verifier. We
are evaluating initial roll-out locations for the pay-per-use
model.
“Bonum Health, our telehealth subsidiary, made
significant strides in the fourth quarter to more rapidly propel
adoption nationwide. We signed an exciting partnership with KPH
Healthcare services, bringing affordable healthcare to the patients
of approximately 100 Kinney Drug retail pharmacies on the East
Coast.
“Throughout the year, we have continued to drive
our business forward, achieving several key milestones in our
internal roadmap with a focus on innovation and development through
our various complementary growth opportunities. This is an exciting
time for Trxade, and I believe we are better positioned to create
sustainable value for our shareholders than at any prior time in
the Company's history,” concluded Mr. Ajjarapu, the Company’s
Chairman and Chief Executive Officer.
Fourth Quarter 2020 Financial Summary
- Revenues for the fourth quarter of 2020, increased 17.1% to $2
million, compared to revenue of $1.7 million in the same quarter
last year. The increase in revenue was primarily due to revenue
generated by the Trxade Platform and Trxade Prime.
- Gross profit in the fourth quarter of 2020, decreased 90.0% to
$0.1 million, or 6.5% of revenues, compared to gross profit of $1.3
million, or 76.5% of revenues, in the same quarter last year. The
decrease in gross profit was primarily attributable to higher costs
associated with Trxade Prime transactions and a write down of
inventory.
- Operating expenses in the fourth quarter of 2020 were $2.4
million, compared to $1.6 million in the same quarter last year.
This increase is primarily due to the Loss on Impairment of
Goodwill of $726,000 and an increase in employees with our
expansion into Business to Consumer (B2C) sales.
- Net loss in the fourth quarter of 2020 was $2.3 million, or
$0.29 per basic and diluted share outstanding, as a result of the
Loss on Impairment of Goodwill and a $1,081,000 inventory write
down, compared to a net loss of $0.5 million, or $0.04 per basic
and diluted share outstanding, in the same quarter last year.
- Adjusted EBITDA, a non-GAAP financial measure, decreased to
($1.4) million for the fourth quarter of 2020, compared to $0.2
million in the same quarter last year.
Fiscal Year Ended December 31, 2020 Summary
- Revenues for the year ended December 31, 2020, increased 130.3%
to $17.1 million, compared to revenue of $7.4 million in the
previous year. The increase in revenue was due to revenue generated
by Trxade Platform, Trxade Prime and Integra Pharma Solutions, our
wholly-owned subsidiary, which revenue increase mainly related to
Personal Protective Equipment (PPE) sales relating to the COVID-19
pandemic.
- Gross profit for 2020 increased 17.2% to $5.7 million, or 33.3%
of revenues, compared to gross profit of $4.8 million, or 65.5% of
revenues, in the same period last year. The increase in gross
profit was attributable to higher costs associated with Trxade
Prime and Integra Pharma transactions.
- Operating expenses for the full year 2020 were $8.2 million,
compared to $4.7 million in the last year. This increase is due to
the Loss on Impairment of Goodwill, an increase in employees with
our expansion into Business to Consumer (B2C) sales, IT
initiatives, and non-cash compensation.
- Net loss for the year ended December 31, 2020, was ($2.5)
million, or ($0.33) per basic and diluted share outstanding,
compared to net loss of ($0.3) million, or ($0.05) per basic and
diluted share outstanding, in the last year.
- Adjusted EBITDA, a non-GAAP financial measure, was $0.1
million, compared to $0.85 million for the year ended 2020 and
2019, respectively.
- Cash and cash equivalents were $5.9 million as of December 31,
2020, compared with $2.9 million as of December 31, 2019.
Conference Call and Webcast
Management will host a conference call on
Monday, March 29, 2021 at 5:00 p.m. Eastern time to discuss Trxade
Group’s fourth quarter and fiscal year 2020 financial results. The
call will conclude with Q&A from participants. To participate,
please use the following information:
Q4 and Fiscal Year 2020 Conference Call and
Webcast Date: Monday, March 29,
2021 Time: 5:00 p.m. Eastern time U.S. Dial-in: 1-877-425-9470
International Dial-in: 1-201-389-0878 Conference ID: 13716956
Webcast: http://public.viavid.com/index.php?id=143721
Please dial in at least 10 minutes before the
start of the call to ensure timely participation.
A playback of the call will be available through
April 29, 2021. To listen, call 1-844-512-2921 within the United
States or 1-412-317-6671 when calling internationally and enter
replay pin number 13716956. A webcast will also be available for 30
days on the IR section of the Trxade Group website or by clicking
the webcast link above.
About Trxade Group,
Inc.
Trxade Group (NASDAQ: MEDS) is a health services
IT company focused on digitalizing the retail pharmacy experience
by optimizing drug procurement, the prescription journey and
patient engagement in the U.S. The Company operates the TRxADE drug
procurement marketplace serving a total of 11,800+ members
nationwide, fostering price transparency and under the Bonum Health
brand, offering patient centric telehealth services. For more
information on Trxade Group, please visit the Company’s IR website
at investors.trxadegroup.com.
Use of Non-GAAP Financial
Information
This earnings release discusses EBITDA and
Adjusted EBITDA. These measurements are not recognized in
accordance with generally accepted accounting principles (GAAP) and
should not be viewed as an alternative to GAAP measures of
performance. EBITDA represents net income before interest, taxes,
depreciation and amortization. Adjusted EBITDA is defined as EBITDA
before stock-based compensation expense and gain (loss) in equity
investment. EBITDA and Adjusted EBITDA are presented because we
believe they provide additional useful information to investors due
to the various noncash items during the period. EBITDA and Adjusted
EBITDA have limitations as analytical tools, and you should not
consider them in isolation, or as a substitute for analysis of our
operating results as reported under GAAP. Some of these limitations
are: EBITDA and Adjusted EBITDA do not reflect cash expenditures,
future requirements for capital expenditures, or contractual
commitments; EBITDA and Adjusted EBITDA do not reflect changes in,
or cash requirements for, working capital needs; and EBITDA and
Adjusted EBITDA do not reflect the significant interest expense, or
the cash requirements necessary to service interest or principal
payments, on debt or cash income tax payments. Although
depreciation and amortization are noncash charges, the assets being
depreciated and amortized will often have to be replaced in the
future, and EBITDA and Adjusted EBITDA do not reflect any cash
requirements for such replacements. Additionally, other companies
in our industry may calculate EBITDA and Adjusted EBITDA
differently than Trxade Group, Inc. does, limiting its usefulness
as a comparative measure. See also “Reconciliation of Net Income
attributable to Trxade Group, Inc., to Earnings before Interest,
Taxes, Depreciation and Amortization (EBITDA) and Adjusted EBITDA”,
below.
Forward-Looking StatementsThis
press release may contain forward-looking statements, including
information about management’s view of Trxade’s future
expectations, plans and prospects, within the safe harbor
provisions under The Private Securities Litigation Reform Act of
1995 (the “Act”). In particular, when used in the preceding
discussion, the words “may,” “could,” “expect,” “intend,” “plan,”
“seek,” “anticipate,” “believe,” “estimate,” “predict,”
“potential,” “continue,” “likely,” “will,” “would” and variations
of these terms and similar expressions, or the negative of these
terms or similar expressions are intended to identify
forward-looking statements within the meaning of the Act, and are
subject to the safe harbor created by the Act. Any statements made
in this news release other than those of historical fact, about an
action, event or development, are forward-looking statements. These
statements involve known and unknown risks, uncertainties and other
factors, which may cause the results of Trxade, its divisions and
concepts to be materially different than those expressed or implied
in such statements. These risks include risks of our operations not
being profitable; claims relating to alleged violations of
intellectual property rights of others; technical problems with our
websites; risks relating to implementing our acquisition
strategies; our ability to manage our growth; negative effects on
our operations associated with the opioid pain medication health
crisis; regulatory and licensing requirement risks; risks related
to changes in the U.S. healthcare environment; the status of our
information systems, facilities and distribution networks; risks
associated with the operations of our more established competitors;
regulatory changes; healthcare fraud; COVID-19, governmental
responses thereto, economic downturns and possible recessions
caused thereby; changes in laws or regulations relating to our
operations; privacy laws; system errors; dependence on current
management; our growth strategy; and others that are included from
time to time in filings made by Trxade with the Securities and
Exchange Commission, including, but not limited to, in the “Risk
Factors” sections in its Form 10-Ks and Form 10-Qs and in its Form
8-Ks, which it has filed, and files from time to time, with the
U.S. Securities and Exchange Commission. These reports are
available at www.sec.gov. Other unknown or unpredictable factors
also could have material adverse effects on Trxade’s future results
and/or could cause our actual results and financial condition to
differ materially from those indicated in the forward-looking
statements. The forward-looking statements included in this press
release are made only as of the date hereof. Trxade cannot
guarantee future results, levels of activity, performance or
achievements. Accordingly, you should not place undue reliance on
these forward-looking statements. We undertake no obligation to
update publicly any of these forward-looking statements to reflect
actual results, new information or future events, changes in
assumptions or changes in other factors affecting forward-looking
statements, except to the extent required by applicable laws. If we
update one or more forward-looking statements, no inference should
be drawn that we will make additional updates with respect to those
or other forward-looking statements.
Investor Relations: Lucas Zimmerman Senior Vice
President MZ Group - MZ North America (949) 259-4987
MEDS@mzgroup.us www.mzgroup.us
Trxade Group,
Inc.Consolidated Balance
SheetsDecember 31, 2020 and 2019
|
|
December 31, 2020 |
|
|
December 31, 2019 |
|
Assets |
|
|
|
|
|
|
|
|
Current
Assets |
|
|
|
|
|
|
|
|
Cash |
|
$ |
5,919,578 |
|
|
$ |
2,871,694 |
|
Accounts Receivable, net |
|
|
805,043 |
|
|
|
792,050 |
|
Inventory |
|
|
1,257,754 |
|
|
|
56,761 |
|
Prepaid Assets |
|
|
151,248 |
|
|
|
82,452 |
|
Other Receivables |
|
|
1,087,675 |
|
|
|
- |
|
Total Current Assets |
|
|
9,221,298 |
|
|
|
3,802,957 |
|
|
|
|
|
|
|
|
|
|
Property Plant and
Equipment, Net |
|
|
162,397 |
|
|
|
174,987 |
|
|
|
|
|
|
|
|
|
|
Other
Assets |
|
|
|
|
|
|
|
|
Deposits |
|
|
21,636 |
|
|
|
21,636 |
|
Deferred offering costs |
|
|
- |
|
|
|
88,231 |
|
Right of use leased assets |
|
|
387,371 |
|
|
|
757,710 |
|
Goodwill |
|
|
- |
|
|
|
725,973 |
|
|
|
|
|
|
|
|
|
|
Total
Assets |
|
$ |
9,792,702 |
|
|
$ |
5,571,494 |
|
|
|
|
|
|
|
|
|
|
Liabilities and Stockholders’ Equity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Current
Liabilities |
|
|
|
|
|
|
|
|
Accounts Payable |
|
$ |
256,829 |
|
|
$ |
334,614 |
|
Accrued Liabilities |
|
|
219,256 |
|
|
|
98,852 |
|
Current Portion – Operating Lease Liabilities |
|
|
131,153 |
|
|
|
87,350 |
|
Customer Deposits |
|
|
10,000 |
|
|
|
- |
|
Notes Payable – Related Party |
|
|
225,000 |
|
|
|
- |
|
Total Current Liabilities |
|
|
842,238 |
|
|
|
520,816 |
|
|
|
|
|
|
|
|
|
|
Long Term
Liabilities |
|
|
|
|
|
|
|
|
Notes Payable – Related Party |
|
|
- |
|
|
|
225,000 |
|
Operating Lease Liabilities, net of current portion |
|
|
271,306 |
|
|
|
685,461 |
|
Total
Liabilities |
|
|
1,113,544 |
|
|
|
1,431,277 |
|
|
|
|
|
|
|
|
|
|
Stockholders’
Equity |
|
|
|
|
|
|
|
|
Series A Preferred Stock, $0.00001 par value; 10,000,000 shares
authorized; none issued and outstanding as of December 31, 2020 and
December 31, 2019, respectively |
|
|
- |
|
|
|
- |
|
Common Stock, $0.00001 par value; 100,000,000 shares authorized;
8,093,199 and 6,539,415 shares issued and outstanding as of
December 31, 2020 and 2019, respectively |
|
|
81 |
|
|
|
65 |
|
Additional Paid-in Capital |
|
|
19,610,631 |
|
|
|
12,535,655 |
|
Retained Deficit |
|
|
(10,931,554 |
) |
|
|
(8,395,503 |
) |
Total Stockholders’ Equity |
|
|
8,679,158 |
|
|
|
4,140,217 |
|
|
|
|
|
|
|
|
|
|
Total Liabilities and
Stockholders’ Equity |
|
$ |
9,792,702 |
|
|
$ |
5,571,494 |
|
Trxade Group,
Inc.Consolidated Statements of
OperationsYears Ended December 31, 2020 and
2019
|
|
2020 |
|
|
2019 |
|
Revenues, net |
|
$ |
17,122,520 |
|
|
$ |
7,436,264 |
|
Cost of Sales |
|
|
11,415,198 |
|
|
|
2,565,500 |
|
Gross Profit |
|
|
5,707,322 |
|
|
|
4,870,764 |
|
|
|
|
|
|
|
|
|
|
Operating Expenses |
|
|
|
|
|
|
|
|
Loss on write-off of software asset |
|
|
- |
|
|
|
368,520 |
|
Loss on Impairment of Goodwill |
|
|
725,973 |
|
|
|
- |
|
General and Administrative |
|
|
7,488,011 |
|
|
|
4,377,020 |
|
Total Operating Expenses |
|
|
8,213,984 |
|
|
|
4,745,540 |
|
|
|
|
|
|
|
|
|
|
Operating Income (Loss) |
|
|
(2,506,662 |
) |
|
|
125,224 |
|
|
|
|
|
|
|
|
|
|
Other Income |
|
|
- |
|
|
|
72,075 |
|
Investment Loss |
|
|
- |
|
|
|
(250,000 |
) |
Loss on Extinguishment of Debt |
|
|
- |
|
|
|
(178,500 |
) |
Interest Expense |
|
|
(29,389 |
) |
|
|
(53,227 |
) |
Net Loss |
|
$ |
(2,536,051 |
) |
|
$ |
(284,428 |
) |
|
|
|
|
|
|
|
|
|
Net Loss per Common Share – Basic and Diluted |
|
$ |
(0.33 |
) |
|
$ |
(0.05 |
) |
|
|
|
|
|
|
|
|
|
Weighted average Common Shares Outstanding Basic and Diluted |
|
|
7,705,620 |
|
|
|
5,929,092 |
|
Trxade Group,
Inc.Consolidated Statements of Cash
FlowsYears ended December 31, 2020 and
2019
|
|
2020 |
|
|
2019 |
|
Operating
Activities: |
|
|
|
|
|
|
|
|
Net loss |
|
$ |
(2,536,051 |
) |
|
$ |
(284,428 |
) |
|
|
|
|
|
|
|
|
|
Adjustments to reconcile net income (loss) to net cash provided by
operating activities: |
|
|
|
|
|
|
|
|
Depreciation Expense |
|
|
5,500 |
|
|
|
5,000 |
|
Options Expense |
|
|
448,404 |
|
|
|
176,376 |
|
Warrant Expense |
|
|
56,885 |
|
|
|
105,452 |
|
Common Stock Issued for Services |
|
|
1,357,759 |
|
|
|
- |
|
Bad Debt Expense |
|
|
10,539 |
|
|
|
11,500 |
|
Loss on extinguishment of debt |
|
|
- |
|
|
|
178,500 |
|
Investment Loss |
|
|
- |
|
|
|
250,000 |
|
Loss on write off of software asset |
|
|
- |
|
|
|
277,500 |
|
Loss on Impairment of Goodwill |
|
|
725,973 |
|
|
|
- |
|
Loss on write-down of Inventory |
|
|
1,218,020 |
|
|
|
- |
|
Amortization of Right-of-Use Asset |
|
|
97,020 |
|
|
|
89,731 |
|
Changes in operating assets and liabilities: |
|
|
|
|
|
|
|
|
Accounts Receivable |
|
|
(23,532 |
) |
|
|
(369,923 |
) |
Prepaid Assets and Other Current Assets |
|
|
(68,796 |
) |
|
|
475 |
|
Other Assets |
|
|
- |
|
|
|
(89,336 |
) |
Inventory |
|
|
(2,419,013 |
) |
|
|
23,205 |
|
Other Receivables |
|
|
(1,087,675 |
) |
|
|
- |
|
Lease Liability |
|
|
(97,033 |
) |
|
|
(74,630 |
) |
Accounts Payable |
|
|
(33,190 |
) |
|
|
(148,659 |
) |
Accrued Liabilities and Other Liabilities |
|
|
120,404 |
|
|
|
(8,988 |
) |
Customer Deposits |
|
|
10,000 |
|
|
|
- |
|
Net Cash provided by (used in) operating activities |
|
|
(2,214,786 |
) |
|
|
141,775 |
|
|
|
|
|
|
|
|
|
|
Investing
Activities: |
|
|
|
|
|
|
|
|
Purchase of Fixed Assets |
|
|
(37,505 |
) |
|
|
(82,252 |
) |
Purchase of Equity Method Investment |
|
|
- |
|
|
|
(250,000 |
) |
Net Cash Used in Investing
Activities |
|
|
(37,505 |
) |
|
|
(332,252 |
) |
|
|
|
|
|
|
|
|
|
Financing
Activities: |
|
|
|
|
|
|
|
|
Repayments of Short-Term Convertible Debt – Related Parties |
|
|
- |
|
|
|
(262,552 |
) |
Payment of Stock Issuance Costs |
|
|
(732,356 |
) |
|
|
- |
|
Proceeds from Exercise of Warrants |
|
|
37,606 |
|
|
|
166 |
|
Proceeds from Exercise of Stock Options |
|
|
501 |
|
|
|
- |
|
Proceeds from Issuance of Common Stock |
|
|
5,994,424 |
|
|
|
2,455,000 |
|
Net Cash provided by financing activities |
|
|
5,300,175 |
|
|
|
2,192,614 |
|
|
|
|
|
|
|
|
|
|
Net increase in Cash |
|
|
3,047,884 |
|
|
|
2,002,137 |
|
Cash at Beginning of the
Year |
|
|
2,871,694 |
|
|
|
869,557 |
|
Cash at End of the Year |
|
$ |
5,919,578 |
|
|
$ |
2,871,694 |
|
|
|
|
|
|
|
|
|
|
Supplemental Cash Flow
Information |
|
|
|
|
|
|
|
|
Cash Paid for Interest |
|
$ |
29,442 |
|
|
$ |
98,461 |
|
Cash Paid for Income
Taxes |
|
$ |
- |
|
|
$ |
- |
|
|
|
|
|
|
|
|
|
|
Non-Cash
Transactions |
|
|
|
|
|
|
|
|
Recognition of ROU assets and
operating lease obligations |
|
$ |
- |
|
|
$ |
847,441 |
|
Purchase of Fixed Assets
recorded in Accounts Payable |
|
$ |
- |
|
|
$ |
82,729 |
|
Common Stock Issued for
Conversion of Note and Accrued Interest |
|
$ |
- |
|
|
$ |
386,983 |
|
Remeasurement of ROU Assets
and Lease Liability for Nonrenewal of Lease |
|
$ |
273,319 |
|
|
$ |
- |
|
Reconciliation of Net Income (Loss) attributable to Trxade
Group, Inc., to Earnings before Interest, Taxes, Depreciation and
Amortization (EBITDA) and Adjusted EBITDA* |
|
|
|
|
|
|
|
|
|
For the three months ended December 31, |
|
|
Fiscal Year ended December 31, |
|
|
|
|
2020 |
|
|
|
|
2019 |
|
|
|
|
2020 |
|
|
|
|
2019 |
|
|
Net Income (Loss) attributable to Trxade Group, Inc. |
|
$ |
(2,312,162 |
) |
|
|
$ |
(495,203 |
) |
|
|
$ |
(2,536,051 |
) |
|
|
$ |
(284,428 |
) |
|
Add (deduct): |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest, net |
|
|
6,725 |
|
|
|
|
6,410 |
|
|
|
|
29,389 |
|
|
|
|
53,227 |
|
|
Depreciation and amortization |
|
|
1,750 |
|
|
|
|
1,250 |
|
|
|
|
5,500 |
|
|
|
|
5,000 |
|
|
EBITDA |
|
|
(2,303,687 |
) |
|
|
|
(487,543 |
) |
|
|
|
(2,501,162 |
) |
|
|
|
(226,201 |
) |
|
Add (deduct): |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share in Equity losses on Investment |
|
|
- |
|
|
|
|
- |
|
|
|
|
- |
|
|
|
|
250,000 |
|
|
Loss on write-off of software asset |
|
|
- |
|
|
|
|
368,520 |
|
|
|
|
- |
|
|
|
|
368,520 |
|
|
Loss on extinguishment of debt |
|
|
- |
|
|
|
|
178,500 |
|
|
|
|
- |
|
|
|
|
178,500 |
|
|
Loss on impairment of Goodwill |
|
|
725,973 |
|
|
|
|
- |
|
|
|
|
725,973 |
|
|
|
|
- |
|
|
Stock-based compensation |
|
|
162,877 |
|
|
|
|
113,871 |
|
|
|
|
1,863,048 |
|
|
|
|
281,828 |
|
|
Adjusted EBITDA * |
|
$ |
(1,414,837 |
) |
|
|
$ |
178,348 |
|
|
|
$ |
87,859 |
|
|
|
$ |
852,647 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
* EBITDA and Adjusted EBITDA are non-GAAP
financial measures. These measurements are not recognized in
accordance with GAAP and should not be viewed as an alternative to
GAAP measures of performance. |
|
TRxADE HEALTH (NASDAQ:MEDS)
Historical Stock Chart
From Mar 2024 to Apr 2024
TRxADE HEALTH (NASDAQ:MEDS)
Historical Stock Chart
From Apr 2023 to Apr 2024